Ascendis Pharma announces EC approval of YORVIPATH

Ascendis Pharma announced that the European Commission, EC, has granted marketing authorization for YORVIPATH as replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. YORVIPATH is a prodrug of parathyroid hormone administered once daily. Ascendis plans its first European Union launch of YORVIPATH in January 2024 in Germany. The EC approval follows the positive opinion adopted on September 14, 2023 by the Committee for Medicinal Products for Human Use of the European Medicines Agency recommending approval of YORVIPATH. “By focusing on patient need and using science to drive our decisions, we have brought YORVIPATH – our second approved TransCon product – from concept through EU marketing authorization in only eight years and we are preparing to launch it in Germany this coming January,” said Jan Mikkelsen, President and Chief Executive Officer at Ascendis Pharma. “Knowing the urgent need that many patients and physicians have expressed for new treatment options, we will continue our work to make YORVIPATH widely available.”